Aflibercept
23 October 2024 | Biocon Switching Study for Aflibercept Confirms Safety & Efficacy
On 23 October 2024, Biocon announced follow-up results from a Phase 3...
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Naomi Pearce, Chantal Savage, Nathan Kan | Oct 28, 2024
Aflibercept
23 October 2024 | Biocon Switching Study for Aflibercept Confirms Safety & Efficacy
On 23 October 2024, Biocon announced follow-up results from a Phase 3...
By Bioblast Editor | Oct 25, 2024
On 25 October 2024, Sanofi announced its Q3 2024 results, including strong growth for Dupixent® (dupilumab) across indications and geographies. Sanofi reports that sales of Dupixent® for the quarter have increased globally by 24% to €3.5 billion and are expected to total a...
By Naomi Pearce, Helen Macpherson, Chantal Savage | Oct 24, 2024
Sandoz AG v Bayer Intellectual Property GmbH [2024] FCAFC 135
Date of decision:
23 October 2024
Body:
Full Court of the Federal Court of...
By Bioblast Editor | Oct 24, 2024
On 24 October 2024, MSD announced that Keytruda® (pembrolizumab) has received marketing approvals from the European Commission for two new gynaecological cancer indications. This means Keytruda® is now approved for 30 indications in Europe, including 5 for gynaecological c...
By Naomi Pearce, Helen Macpherson, Nathan Kan | Oct 23, 2024
ResMed Pty Ltd v Fisher & Paykel Healthcare Limited [2024] APO 30
Date of decision:
05 July 2024
Body:
Australian Patent Office
By Bioblast Editor | Oct 23, 2024
On 23 October 2024, Biocon announced follow-up results from a Phase 3 study of MYL-1701P, biosimilar to Regeneron’s Eylea® (aflibercept). According to Biocon, the study demonstrated switching patients with diabetic macular oedema (DME) from Eylea® to MYL-1701P produced com...
By Bioblast Editor | Oct 23, 2024
On 23 October 2024, Johnson & Johnson (J&J) announced that the European Commission has approved an indication extension for Darzalex® (daratumumab) subcutaneous formulation in combination with bortezomib, lenalidomide and dexamethasone for adult patients with newly ...
By Bioblast Editor | Oct 23, 2024
On 23 October 2024, Eli Lilly announced that its Kisunla™ (donanemab-azbt) received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients ...
By Bioblast Editor | Oct 23, 2024
Samsung Biologics has announced its Q3/2024 financial results, reporting that its accumulated revenue has surpassed KRW 3T for the first time and raising its annual revenue growth guidance to +15-20%. Samsung’s consolidated revenue reached KRW 1.2T for the quarter, an incr...
By Paul Johns, Kimberley Evans, Imogen Bain | Oct 22, 2024
New Zealand Intellectual Property Office- Trade Marks [2024] NZIPOTM 31 (06 August 2024)
Date of decision:
06 August 2024
Body:
IPONZ
SUBSCRIBE TO PEARCE IP